Genetic predisposition to neuroblastoma (NB) is relatively rare. Only 1% to 2% of patients
have a family history of NB, 3% to 4% of cases present with bilateral or multifocal primary …

In the past two decades, technological advances have brought unprecedented insights into
the paediatric cancer genome revealing characteristics distinct from those of adult cancer …

With the increasing use of comprehensive germline genetic testing of children and
adolescents with cancer, it has become evident that pathogenic variants (PVs) in adult-onset …

Background Neuroblastoma is an embryonal cancer of the developing sympathetic nervous
system. The genetic contribution of rare pathogenic or likely pathogenic germline variants in …

Variation in DNA repair genes can increase cancer risk by elevating the rate of oncogenic
mutation. Defects in one such gene, MUTYH, are known to elevate the incidence of …

Patients with relapsed/refractory high-risk neuroblastoma (HRNBL) have poor prognoses.
Recent studies found that BARD1 harbored the most significantly enriched pathogenic/likely …

Despite advances in the treatment of high-risk neuroblastoma, approximately half of these
patients die from the disease. Targeted therapy based on synthetic lethality associated with …

This is a valid argument. However, the use of an extreme phenotype case–control design
(eg, by using healthy elderly controls to search for cancer associated genes) has been …

Pediatric solid tumors are rare malignancies that represent a leading cause of death by
disease among children in developed countries. The early age-of-onset of these tumors …

Neuroblastoma (NB) is a pediatric tumor of the sympathetic nervous system. Survival
remains poor for the almost 40% of patients with high-risk NB. Targeted therapy options for …